摘要
目的:系统评价利妥昔单抗联合CHOP(RCHOP)方案治疗非霍奇金淋巴瘤的疗效与安全性。方法:计算机检索Embase(1991～2010年)、PubMed(1991～2010年)、中国期刊全文数据库(1991～2010年)、中国生物医学文献数据库(1991～2010年),收集非霍奇金淋巴瘤患者行RCHOP方案化疗的随机对照试验,以进行质量评价。结果:共纳入8个随机对照试验,包括1 632例患者。Meta分析结果显示,RCHOP与CHOP方案比较,其完全缓解率[RR=1.34,95%CI(1.19,1.51)]及总有效率[RR=1.16,95%CI(1.11,1.22)]差异均有统计学意义,Ⅲ/Ⅳ级化疗相关不良反应发生率的差异无统计学意义。结论:与CHOP方案相比,联合应用利妥昔单抗能增加非霍奇金淋巴瘤患者的完全缓解率和总有效率,且不增加Ⅲ/Ⅳ级化疗相关不良反应。
OBJECTIVE： To evaluate the clinical efficacy and safety of rituximab combined with CHOP chemotherapy （RCHOP） for non-hodgkin lymphoma. METHODS： Retrieved from Embase （1991～2010）, PubMed（1991～2010）, CNKI （1991～ 2010） and CBM（1991～2010）, RCTs on rituximab combined with CHOP chemotherapy for non-hodgkin lymphoma were collected and quality evaluation was carried out. RESULTS： 8 RCTs involving 1 632 patients were included. Results of Meta-analysis showed that significant differences were found in the total effective rate [RR= 1.16, 95% CI（1.11, 1.22）] and complete remission rate [RR= 1.34,95% CI （1.19,1.51）], but not in the incidence of Ⅲ/Ⅳ grade chemotherapy-related ADR between RCHOP chemotherapy and CHOP chemotherapy. CONCLUSION： Compared with CHOP chemotherapy, rituximab combined with CHOP chemotherapy for non-hodgkin lymphoma can improve the total effective rate and complete remission rate. Meanwhile, it doesn＇t in- crease the incidence of Ⅲ/Ⅳ grade chemotherapy-related ADR.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第46期4376-4379,共4页
China Pharmacy
